Infliximab, a TNF-α antibody, showed evident and rapid efficacy in one case of TEN; a "single-shot" administration resulted in the progression of epidermolysis stopping within a few hours, with re-epithelization achieved within 5 weeks (Kreft et al., 2010[83]). This evidence concerns the gene TNF and toxic epidermal necrolysis.